Tokyo (October 1, 2025) - SB TEMPUS Corp. (SB TEMPUS) and Konica Minolta, Inc. (Konica Minolta) announced that on September 30, 2025, SB TEMPUS completed the acquisition of all the shares of Konica Minolta REALM Inc. (Konica Minolta REALM), Konica Minolta's domestic operating company for the precision medicine business. As a result, Konica Minolta REALM changed its name to GenMine Labs Corp. (GenMine Labs) and became a subsidiary of SB TEMPUS. This acquisition of shares is based on the agreement announced by SB TEMPUS and Konica Minolta on January 14, 2025 in the news release “SB TEMPUS Signs Agreement with Konica Minolta to Acquire Shares of Konica Minolta REALM.”

SB TEMPUS is a joint venture between SoftBank Group Corp. and the U.S.-based Tempus AI, Inc. that has a strong track record in proposing appropriate therapies utilizing genetic testing and AI, and aims to support precision medicine through the use of healthcare data and AI. With the acquisition of GenMine Labs, SB TEMPUS was able to quickly launch the genome testing business by leveraging GenMine Labs' extensive knowledge and networks in advanced genetic testing techniques and cancer genome profiling testing. SB TEMPUS will contribute to the development of cancer diagnostics and precision medicine in Japan, along with GenMine Labs moving forward to accelerate further refinement of cancer precision medicine.

The testing services of GenMineTOP Cancer Genome Profiling System continue to be provided at GenMine Labs' domestic genetic testing laboratory in Hino City, Tokyo. Upon obtaining licenses and approvals for the relocation of genetic testing lab, SB TEMPUS plans to transfer it to a new genetic testing lab it establishes.